KDM4
A Critical Driver of Tumorigenesis and Novel Target for Cancer Therapy
The KDM4 family of histone demethylases (KDM4A, B, C, and D) are epigenetic regulators that have been implicated as drivers of tumorigeneic pathways, including gene overexpression, genomic instability, uncontrolled cell proliferation, inhibition of apoptosis, and metastasis. In addition, KDM4 plays an important role in the self-renewal and maintenance of cancer stem cells.
KDM4 overexpression has been associated with many cancer types, including breast, colorectal, esophageal, prostate, and lymphomas. Thus, KDM4 has emerged as an important novel therapeutic target. Tachyon’s TACH101 is the only KDM4 inhibitor in development.
TACH101 (formerly QC8222) is a potent, selective, first-in-class small molecule inhibitor of all KDM4 proteins. Tachyon is currently developing it for the treatment of advanced or metastatic cancers.